Literature DB >> 9185879

Relationship between ANCA and clinical activity in inflammatory bowel disease: variation in prevalence of ANCA and evidence of heterogeneity.

E Abad1, C Tural, E Mirapeix, A Cuxart.   

Abstract

Antineutrophil cytoplasmic antibodes (ANCA) are markers of necrotizing vasculitis. ANCA have been recently detected in the two forms of inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's disease (CD). To assess the possible role of ANCA in the diagnosis and management of IBD we studied the prevalence of ANCA at diagnosis and during follow-up in a group of 89 IBD patients. The relationship between ANCA and clinical features of IBD was investigated. ANCA assayed by indirect immunofluorescence were detected in 38/52 (73%) of the UC patients but only 6/37 (16.6%) of the CD patients (P<0.005) and in none of the controls. In the UC group, but not in the CD group, there was a positive correlation between ANCA and disease activity. The sensitivity and specificity of ANCA for the diagnosis of UC were 73 and 83.7% respectively. The most commonly observed pattern of ANCA in IBD patients was perinuclear: in 84% of the UC and 66.6% of the CD patients positive for ANCA, respectively. However, careful comparison of IFL patterns revealed some distinct features of IBD-associated ANCA when compared to vasculitis-associated ANCA. In addition, most ANCA positive sera from IBD patients were negative for antibodies to proteinase 3 and myeloperoxidase by ELISA. These results suggest that the autoantigens recognized by ANCA are different in patients with IBD from those with necrotising vasculitis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9185879     DOI: 10.1006/jaut.1996.0114

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  9 in total

1.  Inflammatory bowel disease: definition, epidemiology, etiologic aspects, and immunogenetic studies.

Authors:  Bing Xia; JBA Crusius; SGM Meuwissen; AS Pe?a
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

Review 2.  Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Authors:  C Roozendaal; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

3.  Autoantibodies pANCA, GAB and PAB in inflammatory bowel disease: prevalence, characteristics and diagnostic value.

Authors:  Evgenija Homsak; Dusanka Micetić-Turk; Borut Bozic
Journal:  Wien Klin Wochenschr       Date:  2010-05       Impact factor: 1.704

4.  Perinuclear anti-neutrophil cytoplasmic antibodies (p-anca) in chronic ulcerative colitis: experience in a Mexican institution.

Authors:  Jesus K Yamamoto-Furusho; Takeshi Takahashi-Monroy; Omar Vergara-Fernandez; Edgardo Reyes; Luis Uscanga
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

5.  The prevalence and clinical significance of perinuclear anti-neutrophil cytoplasmic antibody in Korean patients with ulcerative colitis.

Authors:  Jin Ha Lee; Jae Hee Cheon; Eun Soo Kim; Moon Jae Chung; Wonseok Kang; Duk Hwan Kim; You Jung Ha; Jae Jun Park; Tae Il Kim; Won Ho Kim
Journal:  Dig Dis Sci       Date:  2009-06-09       Impact factor: 3.199

6.  Characterisation of autoantibodies to neutrophil granule constituents among patients with reactive arthritis, rheumatoid arthritis, and ulcerative colitis.

Authors:  H Locht; T Skogh; A Wiik
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

7.  Psychobiological subtypes of ulcerative colitis: pANCA status moderates the relationship between disease activity and psychological distress.

Authors:  Robert G Maunder; Gordon R Greenberg; Jonathan J Hunter; William J Lancee; A Hillary Steinhart; Mark S Silverberg
Journal:  Am J Gastroenterol       Date:  2006-10-04       Impact factor: 10.864

8.  Anti-lactoferrin antibodies and other types of anti-neutrophil cytoplasmic antibodies (ANCA) in reactive arthritis and ankylosing spondylitis.

Authors:  H Locht; T Skogh; E Kihlström
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

9.  Serologic and fecal markers to predict response to induction therapy in dogs with idiopathic inflammatory bowel disease.

Authors:  Cristiane C Otoni; Romy M Heilmann; Mercedes García-Sancho; Angel Sainz; Mark R Ackermann; Jan S Suchodolski; Jörg M Steiner; Albert E Jergens
Journal:  J Vet Intern Med       Date:  2018-04-06       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.